Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Kostenuik

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
The American Journal of Sports Medicine|February 7, 2023
Denosumab Use in Rats: Letter to the EditorPaul Kostenuik
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|October 16, 2016
Fracture healing physiology and the quest for therapies for delayed healing and nonunionPaul Kostenuik, Faisal M Mirza
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 28, 2006
RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosisHarry K W Kim, Stephanie Morgan-Bagley, Paul Kostenuik
JBMR Plus|April 18, 2022
Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA)Renaud Winzenrieth, Paul Kostenuik, John Boxberger, et al.
Current Osteoporosis Reports|September 26, 2024
Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal MuscleJohn Gostage, Paul Kostenuik, Katarzyna Goljanek-Whysall, et al.
Menopause (New York, N.Y.)|February 25, 2025
Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fractureKristi Tough DeSapri, Bart L Clarke, Paul Kostenuik, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|January 16, 2022
Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal OsteoporosisRenaud Winzenrieth, Ludovic Humbert, John I Boxberger, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|February 22, 2019
Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fractureBeate Lanske, Heidi Chandler, Allen Pierce, et al.
Bone|December 14, 2011
Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging miceMohammad Shahnazari, Denise Dwyer, Vivian Chu, et al.
The American Journal of Pathology|April 25, 2009
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptorMasanobu Ohishi, Riccardo Chiusaroli, Michael Ominsky, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
The American Journal of Sports Medicine|February 7, 2023
Denosumab Use in Rats: Letter to the EditorPaul Kostenuik
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|October 16, 2016
Fracture healing physiology and the quest for therapies for delayed healing and nonunionPaul Kostenuik, Faisal M Mirza
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 28, 2006
RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosisHarry K W Kim, Stephanie Morgan-Bagley, Paul Kostenuik
JBMR Plus|April 18, 2022
Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA)Renaud Winzenrieth, Paul Kostenuik, John Boxberger, et al.
Current Osteoporosis Reports|September 26, 2024
Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal MuscleJohn Gostage, Paul Kostenuik, Katarzyna Goljanek-Whysall, et al.
Menopause (New York, N.Y.)|February 25, 2025
Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fractureKristi Tough DeSapri, Bart L Clarke, Paul Kostenuik, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|January 16, 2022
Abaloparatide Effects on Cortical Volumetric BMD and Estimated Strength Indices of Hip Subregions by 3D-DXA in Women With Postmenopausal OsteoporosisRenaud Winzenrieth, Ludovic Humbert, John I Boxberger, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|February 22, 2019
Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fractureBeate Lanske, Heidi Chandler, Allen Pierce, et al.
Bone|December 14, 2011
Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging miceMohammad Shahnazari, Denise Dwyer, Vivian Chu, et al.
The American Journal of Pathology|April 25, 2009
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptorMasanobu Ohishi, Riccardo Chiusaroli, Michael Ominsky, et al.
Pageof 4